A new evolutionary and pharmacokinetic–pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs

This publication has 34 references indexed in Scilit:

• Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients
  British Journal of Clinical Pharmacology, 2011
• Saturability of Granulocyte Kill of Pseudomonas aeruginosa in a Murine Model of Pneumonia
  Antimicrobial Agents and Chemotherapy, 2011
• Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection
  Nature Genetics, 2011
• An Oracle: Antituberculosis Pharmacokinetics-Pharmacodynamics, Clinical Correlation, and Clinical Trial Simulations To Predict the Future
  Antimicrobial Agents and Chemotherapy, 2011
• Selection of a Moxifloxacin Dose That Suppresses Drug Resistance inMycobacterium tuberculosis,by Use of an In Vitro Pharmacodynamic Infection Model and Mathematical Modeling
  The Journal of Infectious Diseases, 2004
• Isoniazid Pharmacokinetics-Pharmacodynamics in an Aerosol Infection Model of Tuberculosis
  Antimicrobial Agents and Chemotherapy, 2004
• Mutations in Putative Mutator Genes ofMycobacterium tuberculosisStrains of the W-Beijing Family
  Emerging Infectious Diseases, 2003
• Pharmacokinetics-Pharmacodynamics of Rifampin in an Aerosol Infection Model of Tuberculosis
  Antimicrobial Agents and Chemotherapy, 2003
• DNA Alkylation Damage as a Sensor of Nitrosative Stress in Mycobacterium tuberculosis
  Infection and Immunity, 2003
• Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial
  The Lancet, 2002